SCHEMBL29921815

SCHEMBL29921815

COCCNC(=O)C1c2ccccc2C(=O)N(c2ccc(Cl)cc2)C1c1ccc(Cl)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 4/20 0.75
TP53 P04637 1/20 0.75
ALDH1A1 P00352 8/20 0.66
NPSR1 Q6W5P4 6/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
HTT P42858 3/20 0.62
KDM4E B2RXH2 2/20 0.62
MAPT P10636 2/20 0.62
TSHR P16473 1/20 0.53
GAA P10253 1/20 0.51
STING1 Q86WV6 2/20 0.49
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
RAB9A P51151 1/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GLA P06280 1/20 0.46
CASP1 P29466 1/20 0.46
KCNA5 P22460 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2099808 1.00 MDM2 (0.75) MDM2TP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL29921783 0.90 ALDH1A1 (0.66) MDM2TP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL2098618 0.90 ALDH1A1 (0.66) MDM2TP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL2054562 0.85 MDM2 (1.00) MDM2TP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL2054559 0.85 MDM2 (1.00) MDM2TP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL2098874 0.85 MDM2 (1.00) MDM2TP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL2054560 0.85 MDM2 (1.00) MDM2TP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL2054563 0.85 MDM2 (1.00) MDM2TP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL29921819 0.85 MDM2 (1.00) MDM2TP53ALDH1A1NPSR1SMN1; SMN2
SCHEMBL1754886 0.85 MDM2 (0.64) MDM2TP53ALDH1A1NPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4548977-A2 NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES RDP Pharma AG (CH) 2025-05-07 EP disclosed
US-20240208925-A1 ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS PAGS CO., LTD. (KR) 2024-06-27 US disclosed
CN-117377474-A Isoquinoline derivatives as antiviral and antitumor agents RDP制药股份公司 2024-01-09 CN disclosed
EP-4074314-A1 ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS Valdospan GmbH (AT) 2022-10-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208925-A1 ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS TP53, EIF2AK2, VHL MDM2 18/4885TP53 1/4885ALDH1A1 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.